Follow the people · Insider
Krishnaswamy Yeleswaram
Krishnaswamy Yeleswaram files insider transactions with the SEC as a chief development officer of Rapport Therapeutics (RAPP). We hold 10 disclosed purchases and sales filed since 10 June 2024, 3 of them in the last 90 days.
- Files forRAPP
- Disclosed buys and sells10 in all, 3 in the last 90 days
- Last disclosure26 August 2026
Positions held
1 post we hold — a term names its own dates; a run of filings only says when they filed- Filed 6 June 2024 — 25 August 2026Chief Development Officer · Rapport Therapeutics (RAPP)19 Form 4 lines · source: SEC Form 4
Everything they disclosed
19 entries, newest first — one per disclosure report, one per Form 4 line- ▼ sold on the open market 13,160 shares of Rapport TherapeuticsSEC Form 426 August 2026Common Stock · traded 24 August 2026 · filed 26 August 2026
- ▼ sold on the open market 20,799 shares of Rapport TherapeuticsSEC Form 426 August 2026Common Stock · traded 25 August 2026 · filed 26 August 2026
- ▼ sold on the open market 16,201 shares of Rapport TherapeuticsSEC Form 426 August 2026Common Stock · traded 25 August 2026 · filed 26 August 2026
- ▼ sold on the open market 404 shares of Rapport TherapeuticsSEC Form 420 August 2026Common Stock · traded 19 August 2026 · filed 20 August 2026
- ▼ sold on the open market 20,225 shares of Rapport TherapeuticsSEC Form 421 April 2026Common Stock · traded 17 April 2026 · filed 21 April 2026
- ▼ sold on the open market 500 shares of Rapport TherapeuticsSEC Form 414 April 2026Common Stock · traded 10 April 2026 · filed 14 April 2026
- ▼ sold on the open market 9,165 shares of Rapport TherapeuticsSEC Form 414 April 2026Common Stock · traded 13 April 2026 · filed 14 April 2026
- ▼ sold on the open market 10,200 shares of Rapport TherapeuticsSEC Form 414 April 2026Common Stock · traded 14 April 2026 · filed 14 April 2026
- ▼ sold on the open market 360 shares of Rapport TherapeuticsSEC Form 49 April 2026Common Stock · traded 8 April 2026 · filed 9 April 2026
- ▼ sold on the open market 10,115 shares of Rapport TherapeuticsSEC Form 426 March 2026Common Stock · traded 25 March 2026 · filed 26 March 2026
- ▼ sold on the open market 10,115 shares of Rapport TherapeuticsSEC Form 426 March 2026Common Stock · traded 25 March 2026 · filed 26 March 2026
- was granted 120,000 shares of Rapport Therapeutics (a derivative holding)SEC Form 44 February 2026Stock Option (Right to Buy) · traded 2 February 2026 · filed 4 February 2026
- was granted 120,000 shares of Rapport Therapeutics (a derivative holding)SEC Form 44 February 2026Stock Option (Right to Buy) · traded 2 February 2026 · filed 4 February 2026
- was granted 9,000 shares of Rapport TherapeuticsSEC Form 45 January 2026Common Stock · traded 31 December 2025 · filed 5 January 2026
- ▼ sold on the open market 2,840 shares of Rapport TherapeuticsSEC Form 45 January 2026Common Stock · traded 31 December 2025 · filed 5 January 2026
- was granted 9,000 shares of Rapport TherapeuticsSEC Form 45 January 2026Common Stock · traded 31 December 2025 · filed 5 January 2026
- ▼ sold on the open market 2,840 shares of Rapport TherapeuticsSEC Form 45 January 2026Common Stock · traded 31 December 2025 · filed 5 January 2026
- was granted 110,000 shares of Rapport Therapeutics (a derivative holding)SEC Form 44 February 2025Stock Option (Right to Buy) · traded 3 February 2025 · filed 4 February 2025
- was granted 84,904 shares of Rapport Therapeutics (a derivative holding)SEC Form 410 June 2024Stock Option (Right to Buy) · traded 6 June 2024 · filed 10 June 2024
Positions come from the unitedstates/congress-legislators roster, the Office of Government Ethics and the SEC’s Form 4 index. Every disclosed line names its own source and links the document the government published; we print what the filing says and never a price we did not read from it. Headlines and links come from the GDELT Global Knowledge Graph — the story stays with the publisher. The portrait, where we have one, is the public-domain Congressional Bioguide photograph.